$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000112623415000159 Filed on August 06, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$7.445M	$212.0K
YoY Change	3411.79%	-8.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.300M	$2.900M
YoY Change	151.72%	26.09%
% of Gross Profit
Research & Development	$16.13M	$6.475M
YoY Change	149.11%	28.55%
% of Gross Profit
Depreciation & Amortization	$300.0K	$200.0K
YoY Change	50.0%	0.0%
% of Gross Profit
Operating Expenses	$23.39M	$9.338M
YoY Change	150.45%	27.9%
Operating Profit	-$15.94M	-$9.127M
YoY Change	74.67%	29.11%
Interest Expense	$4.000K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$22.00K	-$38.00K
YoY Change	-157.89%	375.0%
Pretax Income	-$15.92M	-$9.164M
YoY Change	73.72%	29.49%
Income Tax	-$1.829M	$0.00
% Of Pretax Income
Net Earnings	-$14.09M	-$9.163M
YoY Change	53.78%	29.48%
Net Earnings / Revenue	-189.27%	-4322.17%
Basic Earnings Per Share	-$0.49	-$0.33
Diluted Earnings Per Share	-$0.49	-$0.33
COMMON SHARES
Basic Shares Outstanding	28.66M shares	27.87M shares
Diluted Shares Outstanding	28.66M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$207.6M	$77.10M
YoY Change	169.26%	30.02%
Cash & Equivalents	$203.4M	$76.86M
Short-Term Investments	$4.200M	$200.0K
Other Short-Term Assets	$11.30M	$400.0K
YoY Change	2725.0%	-20.0%
Inventory
Prepaid Expenses	$11.34M	$446.0K
Receivables
Other Receivables
Total Short-Term Assets	$234.5M	$78.21M
YoY Change	199.76%	28.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.798M	$6.456M
YoY Change	36.28%	8.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$8.798M	$6.456M
YoY Change	36.28%	8.65%
TOTAL ASSETS
Total Short-Term Assets	$234.5M	$78.21M
Total Long-Term Assets	$8.798M	$6.456M
Total Assets	$243.3M	$84.67M
YoY Change	187.29%	26.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.474M	$687.0K
YoY Change	114.56%	-36.15%
Accrued Expenses	$5.954M	$2.891M
YoY Change	105.95%	2.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$556.0K	$190.0K
YoY Change	192.63%	2.15%
Total Short-Term Liabilities	$9.036M	$3.857M
YoY Change	134.28%	-7.35%
LONG-TERM LIABILITIES
Long-Term Debt	$450.0K	$937.0K
YoY Change	-51.97%	-17.01%
Other Long-Term Liabilities	$8.000M	$7.300M
YoY Change	9.59%	-1.35%
Total Long-Term Liabilities	$8.455M	$8.216M
YoY Change	2.91%	-3.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.036M	$3.857M
Total Long-Term Liabilities	$8.455M	$8.216M
Total Liabilities	$17.49M	$12.07M
YoY Change	44.88%	-4.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.03M	-$154.4M
YoY Change	-76.66%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$551.0K	$182.0K
YoY Change	202.75%
Treasury Stock Shares
Shareholders Equity	$225.8M	$72.60M
YoY Change
Total Liabilities & Shareholders Equity	$243.3M	$84.67M
YoY Change	187.29%	26.35%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$14.09M	-$9.163M
YoY Change	53.78%	29.48%
Depreciation, Depletion And Amortization	$300.0K	$200.0K
YoY Change	50.0%	0.0%
Cash From Operating Activities	-$6.400M	-$7.000M
YoY Change	-8.57%	42.86%
INVESTING ACTIVITIES
Capital Expenditures	-$1.500M	-$200.0K
YoY Change	650.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$3.600M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$2.100M	-$200.0K
YoY Change	-1150.0%	-166.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.100M	400.0K
YoY Change	175.0%	33.33%
NET CHANGE
Cash From Operating Activities	-6.400M	-7.000M
Cash From Investing Activities	2.100M	-200.0K
Cash From Financing Activities	1.100M	400.0K
Net Change In Cash	-3.200M	-6.800M
YoY Change	-52.94%	58.14%
FREE CASH FLOW
Cash From Operating Activities	-$6.400M	-$7.000M
Capital Expenditures	-$1.500M	-$200.0K
Free Cash Flow	-$4.900M	-$6.800M
YoY Change	-27.94%	44.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Paid InterestPaid	10000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	341000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	297000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2173000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28718371	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	929606561	USD
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015Q2	nlnk	Allocated Accellerationof Sharebased Compensation Expense AllocatedAccellerationofSharebasedCompensationExpense	2400000	USD
CY2014Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	190404000	USD
CY2015Q2	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	203377000	USD
CY2014Q4	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1023000	USD
CY2015Q2	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1067000	USD
CY2015Q2	nlnk	Genentech Potential Milestones GenentechPotentialMilestones	1000000000	USD
CY2015Q2	nlnk	Genentech Revenue Recognized GenentechRevenueRecognized	2700000	USD
	nlnk	Genentech Revenue Recognized GenentechRevenueRecognized	12200000	USD
CY2014	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	168000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	427000	USD
CY2014Q4	nlnk	Lab Equipment LabEquipment	4110000	USD
CY2015Q2	nlnk	Lab Equipment LabEquipment	4954000	USD
	nlnk	Merck One Time Milestones MerckOneTimeMilestones	20000000	USD
CY2015Q2	nlnk	Merck Revenue Recognized MerckRevenueRecognized	36000	USD
CY2014Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2015Q2	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
	nlnk	Merck Revenue Recognized MerckRevenueRecognized	134000	USD
CY2014	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
CY2014	nlnk	Net Operating Loss Carryfoward Utilized NetOperatingLossCarryfowardUtilized	89100000	USD
CY2014Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	13000	USD
CY2015Q2	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	440000	USD
CY2014Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	12554000	USD
CY2015Q2	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	14380000	USD
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3716000	USD
CY2015Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	12570000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2412000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1474000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9367000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5954000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4955000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5582000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	236838000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	262055000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3600000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9100000	USD
CY2014Q4	us-gaap	Assets Assets	238062000	USD
CY2015Q2	us-gaap	Assets Assets	243250000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	230463000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	234452000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	89000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000	USD
CY2015Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	31000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61291000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76861000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190404000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203377000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15570000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12973000	USD
CY2014Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	12393000	USD
CY2015Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	4202000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27991242	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28679388	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27980849	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28661588	shares
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	280000	USD
CY2015Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	287000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	85000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12966000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1238000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1196000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	936000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1085000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	809000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1900000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7100000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9500000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	517000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	627000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2014Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-8191000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2863000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6114000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7257000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15623000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9164000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18399000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15920000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3061000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1829000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-160000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	255000	USD
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	15604000	USD
CY2015Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2519000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4007000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-125000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	13085000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	42000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	41000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12305000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1167000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	8852000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-327000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3011000	USD
CY2014Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	9000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	13000	USD
CY2015Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	4000	USD
	us-gaap	Interest Paid InterestPaid	13000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	10000	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	45000	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	26000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	43000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6022000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6139000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	34285000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	17491000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238062000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243250000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25021000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9036000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9264000	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8455000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	0	USD
	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2015Q2	us-gaap	Licenses Revenue LicensesRevenue	4165000	USD
	us-gaap	Licenses Revenue LicensesRevenue	33711000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	157000	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	556000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	941000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	450000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28970000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15666000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-297000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6018000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13103000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8711000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	9338000	USD
	us-gaap	Operating Expenses OperatingExpenses	18977000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	23387000	USD
	us-gaap	Operating Expenses OperatingExpenses	49734000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9126000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18431000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15942000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3094000	USD
CY2015Q2	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	2500000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-50000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2015Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	182000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8333000	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11344000	USD
	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	13500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29247000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16103000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	-9164000	USD
	us-gaap	Profit Loss ProfitLoss	-18399000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	-14091000	USD
	us-gaap	Profit Loss ProfitLoss	-2901000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1399000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2220000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7599000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8798000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	18000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	18000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	77000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	78000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6475000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12863000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16130000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34111000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33119000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36032000	USD
CY2014Q2	us-gaap	Revenue From Grants RevenueFromGrants	212000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	546000	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	3280000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	12929000	USD
CY2014Q2	us-gaap	Revenues Revenues	212000	USD
	us-gaap	Revenues Revenues	546000	USD
CY2015Q2	us-gaap	Revenues Revenues	7445000	USD
	us-gaap	Revenues Revenues	46640000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3604000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9121000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	18988	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	329402	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	333508	shares
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1701	shares
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	341000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13534000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9121000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2168000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	203777000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225759000	USD
	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	542	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	222000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	551000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27876652	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27742029	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28661588	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28408474	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for cancer and other diseases. NewLink initiated operations in April 2000.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2005, NewLink created a partially owned subsidiary, BioProtection Systems Corporation (BPS). NewLink contributed certain licensing agreements and other intangible assets for BPS to create vaccines against potential biological terror threats. On January 7, 2011, NewLink acquired all of the minority interest in BPS by merging a newly formed subsidiary of NewLink with BPS, with BPS as the surviving corporation, resulting in NewLink owning all the outstanding capital stock of BPS. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, NewLink created a wholly-owned subsidiary, NewLink International (NI). NewLink plans to conduct all or a portion of its operations outside of the United States through NI. In 2014, NewLink created another wholly owned subsidiary, NewLink Global (NG), which was subsequently merged into NewLink during 2014.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company had a net loss of </font><font style="font-family:inherit;font-size:10pt;">$14.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ending</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the six months ended June 30, 2015, the Company's loss was lower than the three-month period ending </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> primarily as a result of earning a milestone payment during the first quarter of 2015 pursuant to a license and collaboration agreement the Company entered into with Merck, Sharpe and Dohme Corp., or Merck, in 2014. </font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying financial statements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three and six months then ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the ATM Offering prior to </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. In connection with two license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in 2014, as well as an additional milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements well into 2016, although not through commercialization and launch of revenue-producing products. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-15-000159-index-headers.html	Edgar Link	pending
0001126234-15-000159-index.html	Edgar Link	pending
0001126234-15-000159.txt	Edgar Link	pending
0001126234-15-000159-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
newlinklogorgbwtaga01a01a01.jpg	Edgar Link	pending
nlnk-20150630.xml	Edgar Link	completed
nlnk-20150630.xsd	Edgar Link	pending
nlnk-20150630x10q.htm	Edgar Link	pending
nlnk-20150630xex101.htm	Edgar Link	pending
nlnk-20150630xex102.htm	Edgar Link	pending
nlnk-20150630xex103.htm	Edgar Link	pending
nlnk-20150630xex311.htm	Edgar Link	pending
nlnk-20150630xex312.htm	Edgar Link	pending
nlnk-20150630xex321.htm	Edgar Link	pending
nlnk-20150630_cal.xml	Edgar Link	unprocessable
nlnk-20150630_def.xml	Edgar Link	unprocessable
nlnk-20150630_lab.xml	Edgar Link	unprocessable
nlnk-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2015 Q2 Form 10-Q Financial Statement

#000112623415000159 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2015 Q2 Form 10-Q Financial Statement

#000112623415000159 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo